
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie has demonstrated a strong financial trajectory, with management projecting an increase in global sales for its Neuroscience segment to approximately $10.7 billion for 2025, reflecting a solid upward revision driven by contributions from Vyalev, Vraylar, the oral CGRP franchise, and Botox Therapeutic. The company has also raised its fiscal year 2025 earnings per share (EPS) guidance to a range of $12.09-$12.29, representing a positive midpoint adjustment, alongside a revenue guidance increase of $700 million to nearly $59.7 billion. Overall, AbbVie's impressive first quarter of 2025, characterized by robust sales of $13.34 billion and strong performances in its immunology, oncology, and neuroscience franchises, further substantiates a favorable outlook for the company.
Bears say
AbbVie faces significant downside risks that negatively impact its stock outlook, including disappointing commercial execution on key products such as Skyrizi, Rinvoq, and Botox, alongside potential regulatory setbacks affecting their clinical pipeline. The impending erosion of Humira's market share due to the entry of biosimilars, coupled with competitive pressures on its oncology products like Imbruvica, further complicates long-term growth expectations. Additionally, macroeconomic challenges, particularly in the Aesthetics segment and broader industry dynamics, threaten to undermine expected revenues and earnings, with increased costs in SG&A and R&D exacerbating financial outcomes.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares